Bradley’s impressive track record includes being at the forefront of defending Google and Tyson Foods in headline-making antitrust litigations. He also recently played a crucial role in negotiating Tyson’s successful resolution of a significant multidistrict litigation. He helped Momenta Pharmaceuticals resolve a contentious dispute over its blockbuster generic blood thinner enoxaparin, securing a positive outcome after a trial loss before Axinn was retained.

Bradley also maintains a significant practice securing antitrust clearances for major mergers. He was one of the key leaders responsible for obtaining clearance for The Dow Chemical Company’s $130 billion merger with DuPont – one of the largest and most complex merger reviews in history, requiring approval in more than 20 jurisdictions.

Recognized for his notable work, Bradley has been named a “Rising Star” by Law360 and The National Law Journal, reflecting his outstanding track record in handling complex antitrust matters and his reputation for excellence in the field. In 2025, he was honored as “Lawyer of the Year – Under 40” by Global Competition Review, after being short-listed for the same award in 2022. Bradley is also ranked in Chambers and The Legal 500, and was selected for Benchmark Litigation’s “40 & Under” list in both 2023 and 2024. In addition, he is recognized by Lawdragon as a “Leading Global Competition & Antitrust Lawyer” and one of the “500 Leading Litigators in America.”